Validation of Oxygen Nanosensor in Mitochondrial Myopathy

Mitochondrial Diseases Clinical Trial

Official title:

The Development of Minimally Invasive Nanosensor Technology to Quantify Mitochondrial Function in Human Muscle

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04086329
• Other study ID #: 17-014130
• Secondary ID: 5U54NS078059-12
• Status: Recruiting
• Phase: Phase 1
• Start date: January 17, 2023
• Est. completion date: November 1, 2024

Study information

• Verified date: March 2024
• Source: Children's Hospital of Philadelphia
• Contact: Zarazuela Zolkipli-Cunningham
• Phone: (267) 426 4961
• Email: zolkipliz[@]chop.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Past mitochondrial disease treatment studies have been unsuccessful in determining treatment efficacy, and a major factor has been the lack of validated biomarkers in mitochondrial myopathy (MM). There is currently a growing number of potential new treatments to be tested through MM clinical intervention trials, which has created a pressing need for quantitative biomarkers that reliably reflect MM disease severity, progression, and therapeutic response. The purpose of the study is to measure the efficacy of an electrochemical oxygen nanosensor to measure in vivo mitochondrial function in human muscle tissue, and its ability to discriminate MM patients from healthy volunteers. The data and results from this nanosensor study may contribute to current and future research, including improved diagnostic and therapeutic approaches for patients with mitochondrial disease.

Description:

This is an investigational device clinical trial. MM cases and healthy volunteers will undergo nanosensor muscle oxygen measurement in exercised (dominant) forearm muscle during handgrip exercise. The same measurements will be repeated between 7 and 30 days later in the same forearm and at the same time of day for each participant to assess reproducibility. After placement of the nanosensor in the forearm under local anesthesia, the primary outcome measure is nanosensor-muscle oxygen levels. The secondary outcome measure is an assessment of pain.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: November 1, 2024
• Est. primary completion date: November 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria for Healthy Controls

1. Males and females, between the ages of 18 and 65 years, inclusive

2. Provide informed consent for study participation; able to understand and complete the protocol

3. Able to ambulate independently

4. Able to perform bicycle ergometry Inclusion Criteria for MM Cases

1. Males and females, between the ages of 18 and 65 years, inclusive

2. Provide informed consent for study participation; able to understand and complete the protocol

3. Genetically-confirmed MM as defined by a diagnosis of primary mitochondrial disease (PMD) with predominant symptoms of myopathy as expressed by exercise intolerance and muscle weakness and fatigue.

4. Previously enrolled (or will enroll) in Children's Hospital of Philadelphia (CHOP) Institutional Review Board (IRB) study #08-006177 (Falk, PI) or CHOP IRB #16-013364 (Zolkipli, PI)

5. Able to ambulate independently

6. Able to perform bicycle ergometry Exclusion Criteria for All Participants

Subjects will be excluded if any of the following apply:

1. Unable to provide informed consent and complete all study procedures, including ergometry

2. Non-ambulatory or unable to ambulate independently

3. Pregnant

4. Within 1 month of a recent hospital admission due to acute illness

5. Have severe cardiac disease as defined by an ejection fraction of less than 35% and New York Heart Association Functional Classification Class III; or severe pulmonary disease as defined by the need for supplemental O2 therapy or daytime ventilatory support

6. Have a tracheostomy

7. Have a known bleeding disorder and/or family history (first-degree relative) with a known bleeding disorder

8. Daily intake of aspirin or any other anti-platelet therapy which cannot be temporarily discontinued for medical reasons

9. a) Have known or suspected congenital or acquired immune deficiency; b) concurrent use of immunosuppressive drugs, including corticosteroids; c) past history of recurrent (more than 6 times per year) severe (required hospitalization) skin or soft tissue infections; d) history of infection or delayed wound healing after surgery or biopsy; e) known history of neutropenia with absolute neutrophil count less than 500/mm3

10. Undergo chronic steroid treatment as defined by daily oral intake (for more than 1 month) or have existing untreated endocrinopathies, such as hypothyroidism that caused acquired myopathy

11. Prone to hypertrophic scars and keloids

12. Have any other known inherited myopathy, such as Duchenne muscular dystrophy or congenital myopathy

13. Known allergy to lidocaine

14. Have a cognitive impairment that may prevent the ability to complete study procedures

15. Unable to comply with the requirements of the study protocol and/or unsuitable for the study for any reason, in the opinion of the principal investigator

16. Individuals from vulnerable populations (e.g., prisoners/detainees)

17. Participants who are unable to speak and/or read English (as participants will be required to be proficient to complete study procedures)

Related Conditions & MeSH terms

• Mitochondrial Diseases
• Mitochondrial Myopathies
• Muscular Diseases

Intervention

Device:
• Nanosensor
The purpose of the study is to test a device called a "nanosensor", which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA. The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue.

Locations

Country	Name	City	State
United States	The Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Children's Hospital of Philadelphia	National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Nanosensor-muscle oxygen (Torr) levels	Nanosensor measured muscle O2 levels at baseline, during handgrip exercise and after exercise	60 minutes for data collection at each 2 study visits, up to 6 months.
Secondary	Pain and tolerability		At each 2 study visits, up to 6 months.